KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat.

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; ...

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and in combination ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

KRAS mutations are present in up to 45% of colorectal cancer cases, but fewer than 10% involve the KRAS G12C mutation. Sotorasib targets the KRAS G12C protein specifically and is the first KRAS G12C ...

which targets KRAS mutations that are difficult to drug with small molecules or antibodies. Targeting KRAS-driven cancers like colorectal and lung cancer could address a significant unmet medical ...

APC and TP53 mutations are more frequent in left-sided colon cancer, whereas KRAS mutations are more frequent in right-sided colon cancer. Additionally, the location of the tumor also influences ...